Celularity Celularity
  • Home
  • About
    • About Us
    • Leadership
    • Board of Directors
    • Scientific Advisors
    • Manufacturing
    • Biobanking
    • Tour Our Facility
    • Expanded Access Policy
  • Science
    • Power of Placenta
    • NK Cell Platform
    • T Cell Platform
    • Exosomes
    • Advanced Biomaterials
  • Pipeline
  • Newsroom
  • Investors
    • Investor Relations
    • SEC Filings
    • Corporate Governance
  • Careers
Celularity
MENU

COVID-19

Updates

See latest Press Relases
Celularity to Present at H.C. Wainwright’s 26th Annual Global Investment Conference

Celularity to Present at H.C. Wainwright’s 26th Annual Global Investment Conference

5 Sep 2024 3 Minutes 0 917
...
Avatar photo
Celularity Inc.
Celularity Appoints Richard J. Berman to its Board of Directors

Celularity Appoints Richard J. Berman to its Board of Directors

28 Aug 2024 4 Minutes 0 916
...
Avatar photo
Celularity Inc.
Celularity Reports Full Year 2023 Combined Net Sales of $22.8 Million, a 26.7% Increase Over Full Year 2022, and Announces First Half 2024 Expected Combined Net Sales of $26.9 Million Representing 290% Growth Over First Half 2023

Celularity Reports Full Year 2023 Combined Net Sales of $22.8 Million, a 26.7% Increase Over Full Year 2022, and Announces First Half 2024 Expected Combined Net Sales of $26.9 Million Representing 290% Growth Over First Half 2023

31 Jul 2024 14 Minutes 0 917
...
Avatar photo
Celularity Inc.
Celularity Presents Data of The Effect of Its T-Cell Platform on Multiple Hematological And Solid Tumors at the American Society of Clinical Oncology (ASCO) Annual Meeting

Celularity Presents Data of The Effect of Its T-Cell Platform on Multiple Hematological And Solid Tumors at the American Society of Clinical Oncology (ASCO) Annual Meeting

3 Jun 2024 8 Minutes 0 915
...
Avatar photo
Celularity Inc.
Celularity Data Published in Journal for ImmunoTherapy of Cancer Reveals Benefits of Placental Circulating T Cells for CAR-T Therapy

Celularity Data Published in Journal for ImmunoTherapy of Cancer Reveals Benefits of Placental Circulating T Cells for CAR-T Therapy

14 May 2024 8 Minutes 0 919
...
Avatar photo
Celularity Inc.
Load more
Celularity_Nasdaq_CELU-1

Celularity is a biotechnology company developing off-the-shelf placental-derived allogeneic cell therapies including genetically modified and unmodified NK cells, engineered T cells including CAR-T cells, and mesenchymal-like adherent stromal cells (ASCs), targeting indications across cancer, immunologic, infectious, and degenerative diseases.

Company

  • About
  • Leadership
  • Board of Directors
  • Scientific Advisors
  • Tour Our Facility
  • Careers

Science

  • Pipeline
  • NK Cell Platform
  • T Cell Platform
  • Lifebank
  • Advanced Biomaterials
  • Manufacturing

Investors

  • Investor Relations
  • Partnerships
  • SEC Filings
  • Corporate Governance
  • Press Releases

Celularity Inc. © 2024. All rights reserved.     Privacy Policy     Terms & Conditions

Company
  • About
  • Leadership
  • Board of Directors
  • Scientific Advisors
  • Tour Our Facility
  • Careers
Science
  • Pipeline
  • NK Cell Platform
  • T Cell Platform
  • Lifebank
  • Advanced Biomaterials
  • Manufacturing
Investors
  • Investor Relations
  • Partnerships
  • SEC Filings
  • Corporate Governance
  • Press Releases

Celularity Inc. © 2024. All rights reserved.
Privacy Policy     Terms & Conditions